Novo Nordisk A/S (NYSE:NVO) Shares Acquired Rep. C. Scott Franklin

Key Points

• Representative C. Scott Franklin invested between $1,001 and $15,000 in Novo Nordisk A/S shares (NYSE:NVO) on August 4th, 2023.
• Recent changes in analyst ratings for Novo Nordisk include a downgrade from buy to hold by several firms, with a consensus price target of $83.75.
• Novo Nordisk A/S reported $0.97 EPS for the latest quarter, exceeding analyst expectations, and currently has a market capitalization of $234.10 billion.

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 14th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 4th. The trade occurred in the Representative's "FIDELITY ROTH IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Purchased $15,001 - $50,000 in shares of Novo Nordisk A/S NYSE: NVO on 8/4/2025.
• Sold $15,001 - $50,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $50,001 - $100,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $15,001 - $50,000 in shares of Visa NYSE: V on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 6/16/2025.
• Sold $15,001 - $50,000 in shares of McDonald's NYSE: MCD on 6/16/2025.

Novo Nordisk A/S Stock Performance

NVO stock traded up $0.43 during trading hours on Tuesday, hitting $54.18. 19,060,462 shares of the stock were exchanged, compared to its average volume of 11,646,474. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $241.91 billion, a P/E ratio of 14.88, a P/E/G ratio of 1.80 and a beta of 0.63. The company has a 50-day simple moving average of $64.52 and a two-hundred day simple moving average of $70.02. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 45.05%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in the stock. Strategic Investment Solutions Inc. IL increased its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth approximately $29,000. Finally, Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $30,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent research reports. HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research note on Thursday, July 31st. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. TD Cowen cut their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Finally, BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $81.00.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.